Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | BMC Family Practice

Fig. 3

From: Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey

Fig. 3

Average daily dose of phytocannabinoids for the top 5 symptoms/conditions (Ingestion). Respondents were asked, “When recommending either CBD or THC as the principal therapeutic constituent, what daily dose of CBD/THC do you typically recommend for the following symptom(s)/condition(s) when ingestion is the method of administration?”. Respondents only answered for conditions that they treat and were not required to record a response for every symptom/condition. Bars reflect the average mg/day dose of either: a) CBD, most commonly used by respondents for anxiety, arthritis, fibromyalgia, sleep disorders and HA/migraine (Top 5 by frequency); or, b) THC, most commonly used for chronic pain, fibromyalgia, arthritis, sleep disorders and anorexia (Top 5 by frequency). The percent response for each dose is numbered inside the bar graph with the standard deviation (CBD, n = 99; THC, n = 132). (% does not =100% as respondents could choose other options such as “I don’t give quantitative dosing advice”)

Back to article page